Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) jumped 1.52 percent and ended the day at $0.48. The Average Volume of the company is 3.87 Million and P/E (price to earnings) ratio is 0, while Forward P/E ratio is 0.
MLV & Co Initiated its coverage for Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) in a note sent to investors on 20-Mar-15. The research firm Initiated the stock to Buy. Moreover, Burrill Institutional Research issued Initiated rating for the stock on 28-Dec-12. Brean Murray also Initiated the company to Buy on 2-Dec-10, 2016.
The highest price RNN stock touched in the last 12 month was $0.56 and the lowest price it hit in the same period was $0.13. The stock has a Return on Assets of -41.4 percent, Return on Investment of 0 percent and a Return on Equity of -55.3 percent. The company’s market cap is $113.85 Million.
Price Target is an important factor while doing analysis of a stock. According to 2 analysts, Price Target for Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) may hit a high of $3. The average and low price target for the stock are $2.5 and $2, respectively.
Now we look at the Moving Averages, the 200-day is 115.82, the 50-day is 109.24 and the 20-day is 60.15. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also help in determining where it may be possibly heading.
When we look at the recommendation trends, the stock presently has an average brokerage recommendation of 0. Out of 0 brokerage recommendations, 0 gave a Strong Buy, 0 issued a Buy, 0 issued Hold, 0 rated Under-perform and 0 issued a Sell.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) performance during the last one year Improved 50.79 percent, while its year to date (YTD) performance showed a Positive trend of 237.91 percent. The stock Jumped 113.02 percent over the past six months. The stock’s quarterly performance indicates a Positive momentum of 229.33 percent, whereas its last one month trend is Optimistic with 78.85 percent. Its weekly performance showed a upward trend of 26.78 percent.
Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at 0 percent, operating profit margin was 0 percent, whereas gross profit margin stands at 0 percent. Beta factor was calculated at -0.16.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has 199.21 Million shares outstanding and 0 shares were floated in market. The short ratio in the company’s stock is documented at 1.93 and the short float is around of 0%. The stock’s average true range of stands at 0.05, while the relative strength index is 84.08.
Liquidity ratios helps investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 11.1, current ratio was 11.1, LT Debt/Equity ratio was 0 and Total Debt/Equity ratio was 0.